Sudeep Pharma
Sudeep Pharma Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
3 of 4 strong
Not discussed on this call: fundraise.
The short version
Pharma, Food & Nutrition (PFN) segment expects sustained growth, driven mainly by volume expansion, especially phosphates; price increases to reflect more from Q2 onwards. Sudeep Pharma expects continued strong revenue growth and sustained profitability in FY ’27, driven by healthy customer demand and expanding market penetration domestically and internationally.
From Sudeep Pharma's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- Pharma, Food & Nutrition (PFN) segment expects sustained growth, driven mainly by volume expansion, especially phosphates; price increases to reflect more from Q2 onwards.
- Bisglycinate portfolio projected to grow significantly over the next 2-3 years, potentially becoming a top revenue contributor.
- Specialty ingredients business aims to return to historical growth trajectory from Q2 onward after LPG-related supply constraints.
- NSS segment anticipates gradual recovery with single-digit growth in FY’27; expects margin improvement and growth in FY’28 through market diversification and operational improvements.
- Battery materials segment scaling up, qualifying 8 customers; plans to increase capacity from 25 KTPA to 100-200 KTPA by 2030-31, aiming for strong growth in this segment.
- Overall, company targets sustainable growth with improving capacity utilization and expanded international market presence.
Profitability & Margins
See what Sudeep Pharma said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Construction of Sudeep Advanced Materials' Phase 1 is on schedule, targeting commissioning by April 2027.
- Deliveries of major long-lead equipment expected to be completed by October 2026, with ongoing statutory approvals.
- Planning for Phase 2 and Phase 3 expansions is underway, aiming to increase capacity to 100 KTPA.
- Early evaluation started for a further expansion from 100 KTPA to 200 KTPA, pending binding off-take agreements expected later this year.
- Greenfield facility for pharma, food, and nutrition is undergoing regulatory approvals, expected to start supplies from Q3 2026.
- Investments have been made in strengthening the international sales team and expanding capacity with a new greenfield plant commissioning in Q3 2026.
- Capacity expansions target to achieve steady-state utilization and improve asset turns between 2.7x to 3x.
- New Dahej site land supports up to 200 KTPA capacity; further expansion beyond requires new land acquisition.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Sudeep Pharma said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Currently, 21 customers are at the laboratory validation stage.
- 16 customers have progressed to pilot-scale evaluation.
- 7 customers have completed pre-commercial or commercial validation and are engaged in active off-take discussions.
- The company expects to conclude two significant binding off-take agreements later this year.
- There is a strong customer interest beyond current buildout, prompting early evaluation of expansions from 100 KTPA to 200 KTPA capacity.
- The ongoing order book and customer pipeline provide confidence for continued business momentum into the second quarter and beyond.
Sudeep Pharma — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹182 Cr, net profit ₹49 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Sudeep Pharma Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Novartis India Ltd (Q1 FY27)
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
- IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
- Innova Captab Ltd (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharmaceuticals Ltd (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
Frequently Asked Questions
What were Sudeep Pharma Q1 FY27 results?
Pharma, Food & Nutrition (PFN) segment expects sustained growth, driven mainly by volume expansion, especially phosphates; price increases to reflect more from Q2 onwards. Sudeep Pharma expects continued strong revenue growth and sustained profitability in FY ’27, driven by healthy customer demand and expanding market penetration domestically and internationally.
What is Sudeep Pharma share price analysis?
Sudeep Pharma currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 68.8 with a market cap of ₹12,558 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sudeep Pharma planning capital expenditure?
Construction of Sudeep Advanced Materials' Phase 1 is on schedule, targeting commissioning by April 2027.
Keep Sudeep Pharma on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.